There is increasing evidence that the development of noninsulin dependent diabetes mellitus (NIDDM) is presaged many years earlier by the presence of biochemical and other phenotypic features in susceptible individuals. Earlier intervention in such individuals may prevent or slow the occurrence of overt hyperglycemia which, in turn, may limit the morbidity and mortality associated with diabetes. By selecting populations at higher than average risk for the ultimate development of NIDDM, we propose to be able to practically test the following hypothesis: The reduction in risk of developing NIDDM in persons at high risk for the development of diabetes will be dependent on treatment which affects insulin resistance, islet B-cell dysfunction, and/or hepatic glucose production. Interventions which include diet, exercise sulfonylurea drugs, and metformin in a factorial design can address this hypothesis. The Diabetes Center at the Albert Einstein College of Medicine is a multidisciplinary aggregation of scientists and clinicians actively involved in various aspects of diabetes. With the resources and expertise available among individuals in the Center, we will participate in a multicenter NIDDM Prevention Trial. The Albert Einstein Center would be able to contribute to the success of such a Trial for the following reasons: l) a Diabetes Research and Training Center underpinning and the Institutional commitment to addressing issues in underserved populations of New York City; 2) our participation in the Diabetes Control and Complications Trial as a clinical center; 3) the availability of a large, identified population of individuals from racial and ethnic minority groups in the Bronx and Westchester Counties who receive their medical care in Einstein-affiliated programs; 4) an identified and well characterized population of women who had gestational diabetes diagnosed between 1988 and the present, and an annual accrual of an additional cohort of women with gestational diabetes; 5) expertise in the design and implementation of clinical trials; 6) strong research foci of the principal and co-investigators in areas such as pathophysiology and diagnosis as well as nutritional and pharmacologic treatment of NIDDM; 7) members of the treatment team with specific competence in diabetes in Hispanic and in African-American individuals; 8) a new outpatient facility in which to conduct a clinical trial; 9) expertise in related areas such as hypertension control, cardiovascular risk reduction, and behavioral techniques intended to achieve therapeutic goals; and lO) a track record of participating in constructive collaborative efforts to achieve the goals of NIH-initiated multicenter projects. We will participate in the Trial by providing personnel, resources, and study volunteers to achieve the aims of the planning, implementation, and data analysis phases of the proposed 7-year study.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01DK048349-08
Application #
6380895
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Garfield, Sanford A
Project Start
1994-08-15
Project End
2003-06-30
Budget Start
2001-07-01
Budget End
2002-06-30
Support Year
8
Fiscal Year
2001
Total Cost
$1,133,215
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009095365
City
Bronx
State
NY
Country
United States
Zip Code
10461
Kim, Catherine; Aroda, Vanita R; Goldberg, Ronald B et al. (2018) Androgens, Irregular Menses, and Risk of Diabetes and Coronary Artery Calcification in the Diabetes Prevention Program. J Clin Endocrinol Metab 103:486-496
Luchsinger, José A; Ma, Yong; Christophi, Costas A et al. (2017) Metformin, Lifestyle Intervention, and Cognition in the Diabetes Prevention Program Outcomes Study. Diabetes Care 40:958-965
Goldberg, Ronald B; Aroda, Vanita R; Bluemke, David A et al. (2017) Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium. Circulation 136:52-64
Ceglia, Lisa; Nelson, Jason; Ware, James et al. (2017) Association between body weight and composition and plasma 25-hydroxyvitamin D level in the Diabetes Prevention Program. Eur J Nutr 56:161-170
McCaffery, Jeanne M; Jablonski, Kathleen A; Franks, Paul W et al. (2017) Replication of the Association of BDNF and MC4R Variants With Dietary Intake in the Diabetes Prevention Program. Psychosom Med 79:224-233
Zhou, Kaixin; Yee, Sook Wah; Seiser, Eric L et al. (2016) Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nat Genet 48:1055-1059
Kim, Catherine; Barrett-Connor, Elizabeth; Aroda, Vanita R et al. (2016) Testosterone and depressive symptoms among men in the Diabetes Prevention Program. Psychoneuroendocrinology 72:63-71
Walford, Geoffrey A; Ma, Yong; Clish, Clary et al. (2016) Metabolite Profiles of Diabetes Incidence and Intervention Response in the Diabetes Prevention Program. Diabetes 65:1424-33
Kim, C; Christophi, C A; Goldberg, R B et al. (2016) Adiponectin, C-reactive protein, fibrinogen and tissue plasminogen activator antigen levels among glucose-intolerant women with and without histories of gestational diabetes. Diabet Med 33:32-8
Aroda, Vanita R; Edelstein, Sharon L; Goldberg, Ronald B et al. (2016) Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab 101:1754-61

Showing the most recent 10 out of 18 publications